BioCorRx Inc
OTC:BICX

Watchlist Manager
BioCorRx Inc Logo
BioCorRx Inc
OTC:BICX
Watchlist
Price: 0.4 USD 64.41% Market Closed
Market Cap: $10.6m

EV/IC

32.2
Current
747%
Cheaper
vs 3-y average of -5

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
32.2
=
Enterprise Value
$16.9m
/
Invested Capital
$520.1k

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
32.2
=
Enterprise Value
$16.9m
/
Invested Capital
$520.1k

Valuation Scenarios

BioCorRx Inc is trading above its industry average

If EV/IC returns to its Industry Average (1.9), the stock would be worth $0.02 (94% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-95%
Maximum Upside
No Upside Scenarios
Average Downside
95%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 32.2 $0.4
0%
Industry Average 1.9 $0.02
-94%
Country Average 1.5 $0.02
-95%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close

Market Distribution

Higher than 96% of companies in the United States of America
Percentile
96th
Based on 11 657 companies
96th percentile
32.2
Low
0 — 0.9
Typical Range
0.9 — 2.9
High
2.9 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 0.9
Median 1.5
70th Percentile 2.9
Max 566 432.7

BioCorRx Inc
Glance View

Market Cap
10.6m USD
Industry
Health Care

BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.

BICX Intrinsic Value
4.43 USD
Undervaluation 91%
Intrinsic Value
Price $0.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett